Pain is generally controlled through intrinsic pain modulation systems that maintain balance under normal physiological conditions. However, in pathological scenarios such as neuropathic pain, inflammation, or diabetes-induced nerve damage, these syst...
Pain is generally controlled through intrinsic pain modulation systems that maintain balance under normal physiological conditions. However, in pathological scenarios such as neuropathic pain, inflammation, or diabetes-induced nerve damage, these systems can become compromised. This impairment leads to an overactivation of pain pathways and the onset of chronic pain. This study aims to explore key mechanisms involved in pain modulation, with a focus on innovative strategies targeting two distinct pathways to address chronic pain conditions. Chapter 1 investigates the role of glucagon-like peptide-1 (GLP-1) and its derivatives in modulating nociceptive signaling. It highlights how GLP-1-based peptides, particularly exendin 9–39 and exendin 20–29, provide effective relief from acute and chronic pain. These peptides are shown to act on TRPV1 channels, offering significant analgesic effects without triggering thermoregulatory disturbances, thereby presenting a safer alternative for pain management. Chapter 2 explores the c-Met receptor pathway, focusing on the NK1 splice variant of hepatocyte growth factor (HGF). This variant selectively activates c-Met, modulating neuronal excitability through the regulation of voltage-gated sodium channels. The findings underscore its potential in reducing chronic pain while avoiding excessive cell proliferation. By leveraging this pathway, a targeted therapeutic approach can be employed to address chronic pain effectively. Together, these studies shed light on intrinsic pain regulation mechanisms and present innovative therapeutic options for managing chronic pain, providing valuable insights into improving patient outcomes.